What We're Reading: Page 109
Industry reads hand-picked by our editors
Mar 06, 2023
-
The Wall Street Journal
What Is a CEO’s Pay Actually Worth?
-
The Boston Globe
Foundation stirs controversy by charging cancer patients $83,000 for unproven but promising experimental drug
-
Kaiser Health News
Despite Pharma Claims, Illicit Drug Shipments to US Aren’t Full of Opioids. It’s Generic Viagra.
Mar 03, 2023
-
NPR
FDA has new power to hold drugmakers accountable
-
Kaiser Health News
Eli Lilly Slashed Insulin Prices. This Starts a Race to the Bottom.
-
Reuters
U.S. regulators rejected Elon Musk’s bid to test brain chips in humans
-
MIT Technology Review
A technique called Cell Painting could speed drug discovery
Mar 02, 2023
-
Fierce Biotech
Alzheimer’s meds are here, but not for Down syndrome patients
-
Financial Times
Anorexia is the deadliest psychiatric disorder. Could psychedelics help?
-
Endpoints News
A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can’t make enough of it
-
Reuters
Genentech sues Biogen for royalties on blockbuster MS drug
Mar 01, 2023
-
CNN
Covid vaccine maker Novavax says it may not survive
-
The Wall Street Journal
Congress Investigates How Pharma Middlemen Affect Drug Prices
-
Healthcare Dive
Why regulators didn’t challenge Amazon-One Medical deal, despite data concerns
-
Associated Press
How officials cracked case of eyedrops that blinded people
Feb 28, 2023
Feb 27, 2023
Feb 24, 2023
-
The New York Times
After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique
-
Reuters
First Zantac cancer risk trial in California postponed by months
-
Evaluate Vantage
US deal watchdog’s bark could be worse than its bite
-
Nature
Data hint at Russia’s shifting science collaborations after year of war
Previous
